London, Dec 1 (AP) The UK has sealed a deal securing a 0 per cent tariff rate for all UK medicines exported to the US for at least 3 years, officials said Monday, in return for the UK spending more on new medicines.

Under the deal, announced by officials on both sides, the United States government agreed to exempt UK-origin pharmaceuticals, pharmaceutical ingredients, and medical technology from import taxes.

The Trump administration said that in return, UK drugs firms committed to invest more in the US and create more jobs.

As part of the deal, the UK government said it will invest around 25 per cent more in new and effective treatments — the first major increase in such spending in over two decades.

Both sides hailed the deal as a win.

“This vital deal will ensure UK patients get the cutting-edge medicines they need sooner, and our world-leading UK firms keep developing the treatments that can change lives,” Science and Technology Secretary Liz Kendall said.

US Health Secretary Robert F. Kennedy Jr. said the agreement “strengthens the global environment for innovative medicines and brings long-overdue balance to US–UK pharmaceutical trade.” Earlier this year President Donald Trump and British Prime Minister Keir Starmer agreed on a framework for a trade pact that would slash US import taxes on British cars, steel and aluminum in return for greater access to the British market for US products, including beef and ethanol. (AP) GRS GRS

Pharmaceuticals trade deal secures zero tariffs on medicines for three years, tied to increased manufacturer investment commitments. A bilateral arrangement grants a zero-tariff rate on UK-origin pharmaceuticals, pharmaceutical ingredients, and medical technology exported to the United States for at least three years, conditioned on UK drug firms increasing investment and job creation in the United States and on the UK government increasing spending on new treatments.